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Abstract Introduction. Acute or recurrent pancreatitis may be a complication of primary 
hyperparathyroidism and patients with previous episodes of pancreatitis may develop secondary 
diabetes mellitus. Case report. We describe the clinical case of a 52-year old Caucasian man 
diagnosed with chronic recurrent pancreatitis in 2007. The first episode of acute pancreatitis 
occurred in 2002, followed by another 4 episodes in 2004 and 2007. In 2004, papilosfincterectomy 
was implemented with a stent mount that was removed one month later. In 2005, the patient 
underwent a surgical intervention for the diagnosis of chronic lithiasis, and cholecystectomy was 
performed. Additional investigations on the etiology of recurrent chronic pancreatitis, initially 
diagnosed as idiopathic, revealed elevated values of total serum calcium, serum parathormone, and 
the presence of a parathyroid adenoma in the right lower pole of the thyroid. In September 2007, 
parathyroidectomy was performed with a favorable evolution and the remission of the acute 
pancreatitis episodes. The patient had not had any family history of diabetes; in 2017 he was 
diagnosed with diabetes. Conclusion. In cases of recurrent pancreatitis, screening for 
hyperparathyroidism is recommended. Metabolic evaluation is required, because the risk of 
developing diabetes in patients with recurrent pancreatitis is high. 
Keywords  primary hyperparathyroidism, recurrent pancreatitis, secondary diabetes mellitus 
Highlights ✓ In cases of recurrent renal lithiasis or pancreatitis, screening for hyperparathyroidism is 
recommended. 
✓ Metabolic evaluation is required in patients with recurrent pancreatitis because of their 
high risk of developing diabetes. 
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Introduction 
Primary hyperparathyroidism is an endocrine disorder 
generated by the autonomous production of parathyroid 
hormone (PTH). The prevalence of the disease varies 
between 0.1% and 1.0 %, being the third endocrine disease 
after diabetes and thyroid disorder. The affliction is 
generated in most situations by a solitary parathyroid 
adenoma. Other causes of primary hyperparathyroidism 
include: multiple adenoma, hyperplasia of the four glands, 
and parathyroid carcinoma (1). PTH acts on the bones, 
kidneys, and small intestine. In the bones, PTH stimulates 
osteoblasts directly and osteoclasts indirectly, which leads 
to the release of calcium secondary to the resorption of the 
bones. The effects of PTH on the kidneys include: 
increased calcium reabsorption and decreased phosphate 
reabsorption; and activation of the 1 α hydroxylase, an 
enzyme that catalyzes the transformation of 25-
hydroxycholecalciferol (the inactive form of vitamin D) to 
1,25-dihydroxycholecalciferol (the active form of vitamin 
D). In the small intestine, the active form of vitamin D 
ensures the absorption of calcium through two pathways: 
active transcellular and passive paracellular pathway (2, 3). 
The consequences of primary hyperparathyroidism are 
hypercalcemia (but the normocalcemic variant is now 
recognized), hypercalciuria, hypophosphatemia, damage 
of the cortical and trabecular bones, renal, gastrointestinal, 
cardiovascular, neuromuscular, and psychiatric symptoms. 
The clinical form includes symptomatic or asymptomatic 
diseases. Symptomatic primary hyperparathyroidism 
occurs in countries where biochemical screenings are not 
routinely used (4). The introduction of the serum 
AutoAnalyzer in 1970 allowed the identification of 
patients with asymptomatic hypercalcemia, and advances 
in techniques to determine PTH have facilitated the 
diagnosis of primary hyperparathyroidism (5).  
 Acute or recurrent pancreatitis may be a complication 
of primary hyperparathyroidism (6, 7). The prevalence of 
acute or recurrent pancreatitis in patients with primary 
hyperparathyroidism has been estimated, according to 
some studies, between 1.5% and 13% (5). A study 
published in 2009 by Khoo and collaborators contradicts 
previous reports. Their study included 684 patients with 
primary hyperparathyroidism. 10 patients (1.5%) 
developed acute pancreatitis compared to 32 out of the 
1,368 (2.3%) from the control group. The authors 
concluded that there is no causal relationship between 
primary hyperparathyroidism and acute pancreatitis (8).   
 Subjects with previous episodes of pancreatitis may 
develop diabetes mellitus. The prevalence of diabetes 
secondary to pancreatitis is estimated between 5% and 10% 
in the Western population (9, 10). In 2013, Ewald and 
Bretzel suggested several diagnostic criteria for diabetes 
mellitus secondary to pancreatic diseases, as follows:  
   “ 1) the presence of pancreatic exocrine insufficiency, 
2) evidence of pathological pancreatic imaging, 
3) the absence of type 1 diabetes mellitus (T1DM)-
associated autoantibodies ” (11).  
Case Reports 
A 52-year old Caucasian man was diagnosed with 
chronic recurrent pancreatitis in 2007. The diagnosis was 
based on personal pathological history (repeated episodes 
of acute pancreatitis, biochemical, and imagistic 
investigations). A suggestive aspect of chronic pancreatitis 
evidenced by cholangio nuclear magnetic resonance is 
shown in Figures 1, 2, 3.   
 
Figure 1. Axial T1 fat-supressed section: 
pancreas with mild enhancement, with discrete 
estompation of physiological peripheral 
lobulation associated with peripancreatic fat 
stranding and right dilatation of the Wirsung duct 
 
Figure 2.  Coronal T2 single shot long TE section: 
irregular Wirsung duct dilatation associated with 
small peripheral canal dilations 




Figure 3. Axial T2 weighted fat saturated section: 
pericephalic pancreatic fat stranding with fine 
fluid associated collections. 
The first episode of acute pancreatitis occurred in 2002 
when the patient was hospitalized in an emergency 
department with intense pain in the epigastrium with dorsal 
irradiation after a high-fat meal. Upon admission, the 
patient had elevated values of serum amylase (817 U/l: 
normal range: < 100 U/l) and leukocytosis. The abdominal 
ultrasound revealed a slightly enlarged pancreas, non-
homogeneous echotexture, and the absence of intra or extra 
pancreatic collections. The evolution was favorable under 
conservative treatment, with symptomatic remission and 
normalization of serum amylase levels. In October 2004, 
the patient returned to the emergency department with the 
same symptomatology. Paraclinical investigations 
revealed leukocytosis, serum amylase values of 1.300 U/l, 
and fluid in the peritoneal cavity without visible 
collections. Conservative treatment (antispastics, 
antisecretory drugs, anti-enzymatic drugs, antibiotics) led 
to improvement of the clinical symptomatology. In 
November 2004, an endoscopic retrograde cholangio 
pancreatography was performed, which established the 
diagnosis of stenotic papillomatosis. Papilosfincterectomy 
was performed with a stent mount that was removed one 
month later. In 2005, the patient underwent a surgical 
intervention for chronic lithiasis, and cholecystectomy was 
performed. In 2007, the patient presented 3 episodes of 
acute pancreatitis. The imaging investigations 
(computerized tomography and nuclear magnetic 
resonance) highlighted the presence of multiple intraductal 
calculi, and for this reason the extraction of calculi was 
performed with papillotomy and stenting (which had to be 
changed every 6 months). Additional investigations on the 
etiology of recurrent chronic pancreatitis, initially 
diagnosed as idiopathic, revealed elevated values of total 
serum calcium (2.90 mmol/l, 2.99 mmol/l; normal range: 
2.10-2.65 mmol/l) and serum parathormone (448.8 pg/ml; 
normal range 15.0-68.3 pg/dl). The presence of a 
parathyroid adenoma in the right lower pole of the thyroid 
was subsequently highlighted through ultrasound (Figure 4 
and 5) and subsequently by scintigraphy. In September 
2007, a parathyroidectomy was performed. In February 
2008, the imaging control and the laboratory tests (after 
surgery) were performed. The values of total serum 
calcium were 2.49 mmol/l, serum parathormone 112 
pg/ml, and thyroid scintigraphy (after the intravenous 
administration of 74 Mega-Becquerel Technetium 99 m) 
highlighted the homogenous distribution of the radioactive 
tracer without hot or cold areas. After parathyroidectomy, 
the patient showed a favorable evolution with the remission 
of the acute episodes of pancreatitis. The patient did not 
have any family history of diabetes. However, in 2017, he 
was diagnosed with diabetes. From the personal 
pathological history, the patient has been diagnosed with 
renal bilateral lithiasis with repeated eliminations of 
calculi. 
 
Figure 4. Inferior parathyroid adenoma located 
between the carotid-tracheal-cross section   
 
Figure 5. Inferior parathyroid adenoma located 
between the carotid-tracheal-longitudinal section 
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Discussions 
The relationship between primary hyperparathyroidism 
and recurrent nephrolithiasis is well known. The 
prevalence of renal lithiasis has dropped from 60-80% in 
initial studies to 7-20% in the more recent studies (12, 13, 
14). The etiology of nephrolithiasis is multifactorial and 
involves genetic factors, hypercalciuria (a characteristic of 
hyperparathyroidism), hyperoxaluria, and cystinuria (15). 
In 2018, Letavernier and Daudon mention that 
hypercalciuria promotes the formation of kidney stones 
and the most common type of nephrolithiasis is calcium 
oxalate formed at Randall's plaques (16).  
According to the American Gastroenterological 
Association Institute Guideline of Initial Management of 
Acute Pancreatitis, acute pancreatitis is defined as "an 
inflammatory condition of the pancreas that can cause local 
injury, systemic inflammatory response syndrome, and 
organ failure" (17). The etiology of acute pancreatitis 
includes obstructive causes, metabolic abnormalities, 
ischemia, and autoimmune diseases. In 10% of cases, the 
cause cannot be identified and the condition is defined as 
idiopathic pancreatitis (18).  
The relationship between primary hyperparathyroidism 
and acute or chronic recurrent pancreatitis is not fully 
elucidated. Previous studies have highlighted that 
hypercalcemia, which is characteristic to 
hyperparathyroidism, can induce pancreatic injuries (19, 
20, 21). There have been several hypotheses implicating 
hypercalcemia in the development of pancreatitis:   
1. a greater extracellular amount of calcium generates 
the elevation of cytosolic calcium, which activates 
calcineurin and generates the zymogen activation and its 
transformation into trypsin (22, 23, 24). The intracellular 
zymogen activation is one of the earliest events for the 
initiation of acute pancreatitis and the development of 
chronic pancreatitis. Experimental studies mention that 
intracellular trypsin activity generates the apoptosis of the 
acinar cell (25, 26, 27); 
2.  high cytosolic calcium can generate the activation of 
nuclear factor Kappa-B (NF-kB) leading to local and 
systemic inflammation (28, 29); 
3. calcium precipitations generate the formation of 
intraductal stones in the ducts (30).   
Diabetes is associated with pancreatic disorders such as 
ductal pancreatic adenocarcinoma, hemochromatosis, 
pancreatitis, cystic fibrosis, and pancreatic surgery, but 
also with the alteration of bone quality (31). The 
prevalence of diabetes in association with pancreatitis was 
estimated, according to different studies, at 25-80% (32). 
In a study by Pan and al. in 2016 in which 2011 patients 
with chronic pancreatitis were enrolled (1396 men and 615 
women), the authors concluded that men are at higher risk 
of diabetes among patients with pancreatitis than women 
(hazard ratio, 1.51; 95% confidence interval, 1.28–2.33, 
p < 0.001) (33). In chronic pancreatitis, the median age of 
the onset of diabetes mellitus is between 10-25 years (34). 
The consensus statement of PancreasFest 2012 
recommended an annual screening for diabetes in patients 
with chronic pancreatitis by determining the fasting 
glucose and hemoglobin A1c; the impairment of these 
constants requires further investigations (35).    
Conclusions 
In cases of recurrent renal lithiasis or pancreatitis, 
screening for hyperparathyroidism is recommended. 
Metabolic evaluation is required in patients with recurrent 
pancreatitis because of their high risk of developing 
diabetes. 
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